BRPI0617655A2 - composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica - Google Patents

composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica

Info

Publication number: BRPI0617655A2
Authority: BR; Brazil
Prior art keywords: compound; pharmaceutically acceptable; acceptable salt; pharmaceutical formulation; optical isomer
Prior art date: 2005-10-21

Application number

BRPI0617655A

Other languages

English (en)

Inventor

M Brad Nolt

Mark T Bilodeau

Scott Wolkenberg

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-10-21

Filing date

2006-10-17

Publication date

2016-08-23

2006-10-17 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

2016-08-23 Publication of BRPI0617655A2 publication Critical patent/BRPI0617655A2/pt

Links

150000001875 compounds Chemical class 0.000 title abstract 3
230000003287 optical effect Effects 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
150000003839 salts Chemical class 0.000 title 1
102000004257 Potassium Channel Human genes 0.000 abstract 1
206010003119 arrhythmia Diseases 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
108020001213 potassium channel Proteins 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Magnetic Heads (AREA)
Pyridine Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

BRPI0617655A 2005-10-21 2006-10-17 composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica BRPI0617655A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US72907805P	2005-10-21	2005-10-21
PCT/US2006/040409 WO2007050347A1 (en)	2005-10-21	2006-10-17	Potassium channel inhibitors

Publications (1)

Publication Number	Publication Date
BRPI0617655A2 true BRPI0617655A2 (pt)	2016-08-23

Family

ID=37845325

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0617655A BRPI0617655A2 (pt)	2005-10-21	2006-10-17	composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica

Country Status (15)

Country	Link
US (1)	US7973059B2 (pt)
EP (1)	EP1951672B1 (pt)
JP (1)	JP4931930B2 (pt)
KR (1)	KR20080057296A (pt)
CN (1)	CN101291910A (pt)
AT (1)	ATE510822T1 (pt)
AU (1)	AU2006306541B2 (pt)
BR (1)	BRPI0617655A2 (pt)
CA (1)	CA2626402C (pt)
IL (1)	IL190730A0 (pt)
NO (1)	NO20082298L (pt)
NZ (1)	NZ567000A (pt)
RU (1)	RU2008119994A (pt)
WO (1)	WO2007050347A1 (pt)
ZA (1)	ZA200802848B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK2413902T3 (da)	2009-03-18	2019-10-07	Incarda Therapeutics Inc	Enhedsdoser, aerosoler, kits og fremgangsmåder til behandling af hjertetilstande ved pulmonal indgivelse
CA2841142C (en)	2010-06-23	2020-12-15	Ryan D. Morin	Biomarkers for non-hodgkin lymphomas and uses thereof
BR112013005806B1 (pt)	2010-09-10	2022-05-10	Epizyme, Inc	Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
US9175331B2 (en)	2010-09-10	2015-11-03	Epizyme, Inc.	Inhibitors of human EZH2, and methods of use thereof
TW201733984A (zh)	2011-04-13	2017-10-01	雅酶股份有限公司	經取代之苯化合物
JO3438B1 (ar)	2011-04-13	2019-10-20	Epizyme Inc	مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
IL296199B2 (en)	2012-04-13	2024-12-01	Eisai R&D Man Co Ltd	Salt form of a human hi stone methyltransf erase ezh2 inhibitor
AU2013331380B2 (en)	2012-10-15	2018-03-22	Epizyme, Inc.	Substituted benzene compounds
AU2014337300B2 (en)	2013-10-16	2019-01-03	Eisai R&D Management Co., Ltd.	Hydrochloride salt form for EZH2 inhibition
PE20170268A1 (es)	2014-06-19	2017-04-21	Ariad Pharma Inc	Compuestos de heteroarilo para la inhibicion de cinasa
SG10202012584UA (en)	2016-02-01	2021-01-28	Incarda Therapeutics Inc	Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
CA3060702A1 (en)	2017-05-10	2018-11-15	Incarda Therapeutics, Inc.	Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
EP3768378B1 (en)	2018-03-22	2025-08-06	InCarda Therapeutics, Inc.	A novel method to slow ventricular rate
KR20200144579A (ko)	2018-05-14	2020-12-29	어리어드 파마슈티칼스, 인코포레이티드	피리미딘 유도체의 약학 염 및 장애의 치료 방법
IL290088B2 (en)	2019-08-01	2023-10-01	Incarda Therapeutics Inc	A pharmaceutical preparation containing flacainide, cyclodextrin and acid, a dosage unit of the preparation and a kit containing the preparation
US11020384B2 (en)	2019-08-01	2021-06-01	Incarda Therapeutics, Inc.	Antiarrhythmic formulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2005267884B2 (en) *	2004-07-29	2011-04-21	Merck Sharp & Dohme Corp.	Potassium channel inhibitors
EP1776355B1 (en) *	2004-07-29	2013-06-12	Merck Sharp & Dohme Corp.	Potassium channel inhibitors
EP1940406A4 (en) *	2005-10-21	2009-11-18	Merck & Co Inc	POTASSIUM CHANNEL INHIBITORS

2006
- 2006-10-17 EP EP06816997A patent/EP1951672B1/en not_active Not-in-force
- 2006-10-17 US US11/992,919 patent/US7973059B2/en active Active
- 2006-10-17 JP JP2008536717A patent/JP4931930B2/ja not_active Expired - Fee Related
- 2006-10-17 WO PCT/US2006/040409 patent/WO2007050347A1/en not_active Ceased
- 2006-10-17 AU AU2006306541A patent/AU2006306541B2/en not_active Ceased
- 2006-10-17 AT AT06816997T patent/ATE510822T1/de not_active IP Right Cessation
- 2006-10-17 BR BRPI0617655A patent/BRPI0617655A2/pt not_active IP Right Cessation
- 2006-10-17 RU RU2008119994/04A patent/RU2008119994A/ru not_active Application Discontinuation
- 2006-10-17 NZ NZ567000A patent/NZ567000A/en unknown
- 2006-10-17 KR KR1020087009300A patent/KR20080057296A/ko not_active Withdrawn
- 2006-10-17 CA CA2626402A patent/CA2626402C/en not_active Expired - Fee Related
- 2006-10-17 CN CNA2006800388932A patent/CN101291910A/zh active Pending
2008
- 2008-04-01 ZA ZA200802848A patent/ZA200802848B/xx unknown
- 2008-04-08 IL IL190730A patent/IL190730A0/en unknown
- 2008-05-20 NO NO20082298A patent/NO20082298L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2626402A1 (en)	2007-05-03
JP4931930B2 (ja)	2012-05-16
CN101291910A (zh)	2008-10-22
AU2006306541B2 (en)	2011-07-14
WO2007050347A1 (en)	2007-05-03
JP2009512702A (ja)	2009-03-26
US20090042944A1 (en)	2009-02-12
ZA200802848B (en)	2009-01-28
NZ567000A (en)	2010-03-26
CA2626402C (en)	2011-02-15
NO20082298L (no)	2008-07-17
KR20080057296A (ko)	2008-06-24
AU2006306541A1 (en)	2007-05-03
US7973059B2 (en)	2011-07-05
EP1951672A1 (en)	2008-08-06
IL190730A0 (en)	2008-11-03
EP1951672B1 (en)	2011-05-25
ATE510822T1 (de)	2011-06-15
RU2008119994A (ru)	2009-12-10

Similar Documents

Publication	Publication Date	Title
ECSP20027480A (es)	2020-06-30	Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa
BRPI0510177B8 (pt)	2021-05-25	composto, composição farmacêutica e uso do mesmo
BRPI0617655A2 (pt)	2016-08-23	composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
EA200870193A1 (ru)	2009-02-27	Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
BRPI0607796A2 (pt)	2009-06-13	composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica
ECSP088367A (es)	2008-06-30	Derivados de bifenilo y su uso en el tratamiento de la hepatitis c
NO20080865L (no)	2008-04-18	Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer
BRPI0410727A (pt)	2006-06-20	composto, composição farmacêutica, e, uso de um composto
EA200800760A1 (ru)	2008-08-29	ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EA200971081A1 (ru)	2010-10-29	Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
CR9580A (es)	2008-09-23	Inhibidores de la actividad akt
EA200970156A1 (ru)	2009-08-28	Пиридизиноновые производные
BRPI0417717A (pt)	2007-04-03	composto, composição farmacêutica, e, uso de um composto
GT200900283A (es)	2011-10-05	"terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
DOP2006000269A (es)	2007-07-31	Derivados de 4-amino-pirrolotriazina sustituida útiles para el tratamiento de trastornos hiper-proliferativos y enfermedades asociadas con la angiogénesis
BRPI0414581C1 (pt)	2021-05-25	composto, composição farmacêutica compreendendo o referido composto e uso do referido composto
BRPI0617165A2 (pt)	2015-01-06	Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
EA201390908A1 (ru)	2013-12-30	Производные бицикло[3.2.1]октиламида и их применение
CY1109916T1 (el)	2014-09-10	Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
EA200970532A1 (ru)	2009-10-30	Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
BRPI0806789B8 (pt)	2021-05-25	composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
BRPI0408353A (pt)	2006-03-21	composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
EA200970041A1 (ru)	2009-06-30	Ингибиторы акт (протеинкиназы в)
DE602005027540D1 (de)	2011-06-01	Feste formulierungen von ospemifen
BR0313385A (pt)	2005-06-14	Derivados de pirimidina-2,4-diona como inibidores de metaloproteinase da matriz

Legal Events

Date	Code	Title	Description
2012-03-13	B06G	Technical and formal requirements: other requirements [chapter 6.7 patent gazette]	Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 PAR 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.
2013-02-05	B11Z	Dismissal: petition dismissal - article 216, par 2 of industrial property law	Free format text: REFERENTE A PETICAO NO 20080059168/RJ DE 18/04/2008.
2016-08-09	B11M	Decision cancelled [chapter 11.13 patent gazette]	Free format text: O DESPACHO 11.6.1 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0
2016-08-16	B06H	Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]	Free format text: O DESPACHO 6.7 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0
2016-09-27	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 6A, 7A, 8A, 9A E 10A ANUIDADES.
2017-01-17	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.
2021-06-08	B350	Update of information on the portal [chapter 15.35 patent gazette]